Clinical trials · Chicago, IL
Lung cancer clinical trials in Chicago
We’re tracking 151 recruiting lung cancer studies with a site in or near Chicago — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT06598306RecruitingPhase 1
Tarlatamab injection for advanced small cell lung cancer
This trial tests a new drug called tarlatamab, given as an injection under the skin (like a shot), for people with advanced small cell lung cancer that has worsened after chemotherapy. The goal is to see if this treatment can help shrink or slow down the cancer.
Chicago, IllinoisAges 18 years+ - NCT06681220RecruitingPhase 1/Phase 2
Temozolomide and stenoparib for relapsed small cell lung cancer
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Chicago, IllinoisAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Chicago, IllinoisAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Chicago, IllinoisAges 18 years+ - NCT05920356RecruitingPhase 3
Tested KRAS-targeted sotorasib plus chemo vs pembrolizumab plus chemo
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
Chicago, IllinoisAges 18–100 - NCT05898594Recruiting
Lung cancer screening for high-risk Black adults
This study is designed to help Black adults at higher risk get lung cancer screening. It checks whether a screening approach can catch lung problems early and connect people to the right next steps.
Chicago, IllinoisAges 50–80 - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
Chicago, IllinoisAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Chicago, IllinoisAges 18 years+ - NCT04267848RecruitingPhase 3
Testing immunotherapy with chemo after lung cancer surgery
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Chicago, IllinoisAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without another drug for advanced EGFR-mutant lung cancer
This trial tests whether adding a new drug (datopotamab deruxtecan) to the standard targeted therapy osimertinib works better for advanced non-small cell lung cancer with certain EGFR mutations. It is for people who have not had chemotherapy or targeted therapy before.
Chicago, IllinoisAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Chicago, IllinoisAges 18 years+ - NCT04712877Recruiting
Blood and tumor testing to choose the right lung cancer treatment
This trial tests tumor tissue and a blood sample to help doctors pick the most personalized treatment for people with suspected lung cancer. It may help ensure you get therapy matched to your specific tumor characteristics, especially when the cancer might be surgically removed.
Chicago, IllinoisAges Any age - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Chicago, IllinoisAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Chicago, IllinoisAges 40–75 - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Chicago, IllinoisAges 18 years+ - NCT05893888RecruitingPhase 2/Phase 3
Testing three investigational drugs for mouth and lung cancers
This trial tests whether PRV111, PRV211, and PRV131 are safe and work better than expected for certain mouth (lip/oral cavity) cancers and lung cancers. It may help by trying a new approach given directly to the tumor and then monitoring how well it shrinks and how safe it is.
Chicago, IllinoisAges 18–100 - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
Chicago, IllinoisAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Chicago, IllinoisAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Chicago, IllinoisAges 18 years+ - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Chicago, IllinoisAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Chicago, IllinoisAges 18 years+ - NCT06122077Recruiting
Blood test for early lung cancer detection in smokers
This trial tests a blood test that looks for multiple signals to find lung cancer early. If you are a smoker or former smoker over 50, this test might help detect cancer before you have symptoms.
Chicago, IllinoisAges 50 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Chicago, IllinoisAges 18 years+ - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Chicago, IllinoisAges 18 years+
Hear when a new Lung cancer trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Lung cancer trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting lung cancer studies listed above.
- University of Chicago · 7 studies
- University of Illinois · 7 studies
- Northwestern University · 5 studies
- Advocate Christ Medical Center · 3 studies
- Advocate Condell Medical Center · 3 studies
- Advocate Good Samaritan Hospital · 3 studies
- Advocate Good Shepherd Hospital · 3 studies
- Advocate Illinois Masonic Medical Center · 3 studies
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lung cancer studies in Illinois.
Common questions
- Are there lung cancer clinical trials near Chicago?
- Yes. We're currently tracking 151 recruiting lung cancer studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.